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Key messages
What is already known about this subject?
 ► Presence of subclinical inflammation in small joints 
in patients with arthralgia is predictive of rheumatoid 
arthritis (ra) development.
 ► Progression to ra is uncommon in patients 
with arthralgia without Mri-detected subclinical 
inflammation.
What does this study add?
 ► this longitudinal study demonstrated moderate cor-
relations between joints with subclinical inflamma-
tion and joints that developed clinical synovitis.
How might this impact on clinical practice?
 ► these data imply that ia development is a more sys-
temic rather than a locally outgrowing process.
AbstrAct
Introduction Subclinical inflammation, detected by Mri, 
in patients with arthralgia is predictive for development of 
inflammatory arthritis (ia). However, within patients that 
develop ia, the course of inflammation at the joint level 
during this transition is unknown. this longitudinal study 
assessed progression of inflammation at the joint level.
Methods 350 joints (unilateral metacarpophalangeals 
(McPs), wrist, metatarsophalangeal (MtP) joints) of 35 
patients presenting with clinically suspect arthralgia (cSa) 
that progressed to ia were studied at presentation with 
cSa and subsequently when clinical synovitis was first 
identified at joint examination (median time interval 17 
weeks). at both time points, subclinical inflammation (bone 
marrow oedema, synovitis, tenosynovitis) was evaluated 
with Mri and joint examination was performed.
Results at presentation with cSa, 71 joints showed 
subclinical inflammation. During progression to ia, 20% 
of these joints had resolution of inflammation, 60% had 
persistent inflammation and 20% progressed to clinical 
synovitis. Of all joints that had developed clinical synovitis 
(n = 45), no prior subclinical inflammation was detected 
in 69%. Similar results were observed for anticitrullinated 
protein antibodies (acPa)-positive and acPa-negative 
patients.
Conclusions this longitudinal study demonstrated 
moderate correlations between joints with subclinical 
inflammation and joints that developed clinical synovitis. 
these data imply that ia development is a more systemic 
rather than a locally outgrowing process.
InTRoduCTIon
During the prearthritis phases of rheumatoid 
arthritis (RA), subclinical inflammation can 
already be present.1–3 Its presence in small 
joints in patients with arthralgia is predic-
tive of inflammatory arthritis (IA) develop-
ment.1–3 Furthermore, at the patient level, 
progression to IA is uncommon in patients 
with arthralgia without MRI-detected subclin-
ical inflammation.1
Although risk factor studies have made an 
enormous progress in our comprehension 
of the development of RA,4–6 many questions 
remain unanswered. One of these questions 
concerns the progression of inflammation at 
the joint level during development of clin-
ical synovitis. For instance, it is unknown 
how often joints with subclinical inflamma-
tion progress to clinical synovitis in the same 
joint, and vice versa, how often joints with 
clinical synovitis had (prolonged) preceding 
subclinical inflammation at the same location 
during the phase of arthralgia. Consequently, 
it is unclear whether IA development is a 
local outgrowing process where subclinical 
joint inflammation closely relates to subse-
quent clinical synovitis, or whether there is a 
more global deregulation where locations of 
subclinical inflammation and synovitis devel-
opment are largely uncoupled. Exploration 
of these hypotheses necessitates longitudinal 
studies that start in a prearthritis phase.
copyright.
 o
n
 9 August 2019 at W
alaeus Library. Protected by
http://rm
dopen.bmj.com/
R
M
D
 O
pen: first published as 10.1136/rm
dopen-2018-000748 on 7 Septem
ber 2018. Downloaded from
 
2 ten Brinck rM, et al. RMD Open 2018;4:e000748. doi:10.1136/rmdopen-2018-000748
RMD Open
This longitudinal study at the joint level in patients 
with arthralgia that developed IA assessed the course of 
joint inflammation in this period. In sensitivity analyses, 
stratification was applied for anticitrullinated protein 
antibodies (ACPA) status.
MeTHods
Patients
Three hundred and fifty small joints of 35 patients that 
presented withclinically suspect arthralgia (CSA) and 
progressed to IA were evaluated. Patients that presented 
at the rheumatology outpatient clinic of the Leiden 
University Medical Centre were included in a consecutive 
manner in the Leiden CSA cohort between April 2012 
and September 2016. CSA was defined as recent-onset 
(<1 year) arthralgia of small joints that was clinically 
considered at risk for IA by the rheumatologists without 
clinically evident arthritis. Twenty-nine patients (83%) 
met the EULAR definition of arthralgia suspicious for 
progression to RA at baseline.7 Patients included in the 
CSA cohort were followed until synovitis development 
(detected at joint examination by an experienced rheu-
matologist) as described by van Steenbergen et al.8 In 
this study, patients with CSA that were included between 
April 2012 and September 2016 and progressed to IA 
were studied. Regular follow-up visits in the CSA cohort 
were planned at 4, 12 and 24 months after baseline. If 
necessary (for instance when the patient experienced 
more symptoms or noticed a swollen joint) patients were 
seen in between the scheduled visits by their rheumatol-
ogist. This provided early access to rheumatology care if 
patients developed clinically evident synovitis and thus 
IA was identified at the first opportunity. When IA was 
identified at the patient level, individual joints could be 
in one of these states: clinical synovitis, MRI-detected 
subclinical inflammation but no clinical synovitis, or no 
inflammation. Tender joint count (68-TJC) and swollen 
joint count (66-SJC) for study purposes were performed 
by one assessor from a pool of six trained research nurses 
under supervision of an experienced rheumatologist. 
Regular reliability sessions are held to maintain a high 
interobserver correlation. All patients provided written 
informed consent.
Magnetic resonance imaging
Unilateral MRIs of wrist, metacarpophalangeal (MCP)2–5 
and metatarsophalangeal (MTP)1–5 were performed at 
presentation with CSA (most painful side) and at first 
presentation with clinical synovitis (similar side as scanned 
at baseline). An ONI MSK Extreme 1.5 T MRI scanner 
(GE Healthcare, Wisconsin, USA) was used, as described 
previously1 and in the Supplementary Methods. Patients 
were instructed not to use non steroidal anti inflamma-
tory drugs (NSAIDs) 24 hours prior to MRI, with seven 
patients (20%) reporting daily use of NSAIDs at baseline. 
MRIs were evaluated for bone marrow oedema (BME; 
range 0–72)) and synovitis (range 0–33) as described 
by Østergaard et al,9 and tenosynovitis (range 0–54) as 
described by Haavardsholm et al,10 by two independent 
experienced readers who were blind to clinical data and 
the order in time (all had interclass correlations ≥0.94, 
see online supplementary table 1). Subclinical inflamma-
tion was considered present in clinically non-inflamed 
joints if the total inflammation score (summing the BME, 
synovitis and tenosynovitis scores and averaging the score 
of two readers) was ≥1. In other words: if either the BME, 
synovitis or tenosynovitis score was ≥1, subclinical inflam-
mation was considered present in a joint. BME scores for 
the wrist joint were calculated for the bones lining the 
joint space: proximally the radius and ulna, distally the 
proximal carpal row (scaphoid, lunate, triquetrum and 
pisiform). Synovitis scores for the wrist joint were calcu-
lated by the radioulnar and radiocarpal compartment 
and tenosynovitis scores for all wrist flexors and exten-
sors.
Analysis
Percentages were determined by evaluating inflamma-
tion in individual joints over time. Generalised estimating 
equations(GEEs), using an unstructured correlation 
matrix, were used to investigate differences in the time 
interval between the paired measurements in joints that 
did/did not develop clinical synovitis, while holding in 
account that one patient contributed 10 joints. Sensitivity 
analyses were performed per inflammatory feature and 
by stratifying for ACPA status. Finally, a second (more 
stringent) definition was used for subclinical inflamma-
tion: subclinical inflammation was considered present if 
it occurred in <5% of age-matched symptom-free persons 
at the same joint and for the same feature (henceforth 
referred to as 5% corrected definition).
ResulTs
Patient characteristics
Clinical characteristics are demonstrated in online 
supplementary table 2. Ten patients were ACPA-posi-
tive. Thirty-four out of 35 patients (97%) had subclinical 
inflammation in ≥1 joint that was evaluated with MRI at 
baseline. Median duration between presentation with 
CSA and development of IA was 17 weeks (IQR: 6–21). 
When clinical synovitis was identified at one of the subse-
quent visits, the median SJC (66-SJC) was 2 (IQR: 1–5), 
and 23 patients (66%) fulfilled the 2010 ACR/EULAR 
classification criteria for RA.
Joints with subclinical inflammation during CsA 
predominantly remain in state of subclinical inflammation
Further analyses were performed at joint level. At pres-
entation with arthralgia, 71 out of 350 joints showed 
subclinical inflammation on MRI (figure 1). Over time, 
14 of these 71 joints (20%) had resolution of subclinical 
inflammation, 43 joints (60%) had persistent subclinical 
inflammation and 14 joints (20%) progressed to clinical 
synovitis. Two hundred and seventy-nine joints (80%) 
had no subclinical inflammation at baseline imaging.
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Figure 1 Schematic depiction of categories of inflammation 
in 350 small joints during progression from clinically 
suspect arthralgiato inflammatory arthritis. Presence of 
subclinical joint inflammation was detected by MRI. An 
MR inflammation score ≥1 (sum of bone marrow oedema, 
synovitis or tenosynovitis in one joint, average of two 
readers) was defined as subclinical inflammation. At the time 
of IA development, individual joints could show clinically 
detectable joint swelling at physical examination, while 
this was per definition not possible at presentation with 
arthralgia. Please note that the y-axis indicates categories 
of inflammation (below MRI-detection limit of inflammation/
above MRI-detection limit but under clinical detection limit 
of synovitis at physical examination/above clinical detection 
limit of synovitis at physical examination (ie, clinically 
detectable joint swelling)), not absolute MRI-inflammation 
scores.
Next, the absolute total inflammation scores were eval-
uated. The mean change in total inflammation score for 
all patients was 2.0 points (p=0.008). Summing BME, 
synovitis, tenosynovitis scores (yielding the total inflam-
mation score) of the 43 joints that had subclinical inflam-
mation at both time points revealed that 16 joints (37%) 
had increasing inflammation scores (mean increase 1.8 
points), 21 joints (49%) had identical inflammation 
scores and 6 joints (14%) with subclinical inflammation 
had decreasing scores (mean decrease 1.4 points) despite 
still having scores >0 for subclinical inflammation.
Most joints developing clinical synovitis had no preceding 
subclinical inflammation at presentation with CsA
In total, 45 MCP, wrist or MTP joints developed clin-
ically apparent synovitis in 21 patients; 20 joints in the 
feet (MTP) were swollen, whereas 25 joints in the hand 
(MCP or wrist) were swollen. The other 14 patients had 
synovitis in ≥1 joint, but these joints were not evaluated 
on MRI. Of these 45 swollen joints, 31 joints (69%) had 
no preceding subclinical inflammation at presentation 
with arthralgia (figure 1). A GEE investigating if swollen 
joints with or without preceding subclinical inflamma-
tion could have dissimilar times to arthritis revealed no 
difference in time intervals (β=1.3; p=0.71). Hence, the 
absence of preceding subclinical inflammation in joints 
with clinically apparent synovitis was not associated with 
a longer time interval. An MRI example of a joint devel-
oping clinical synovitis whereas it showed no subclinical 
inflammation in the CSA phase is presented in figure 2A.
Analyses were repeated per inflammatory feature, 
revealing that 9% of joints (4 out of 45) with clinical 
synovitis had preceding BMO in the CSA-phase. Simi-
larly, 24% (11 out of 45 joints) had prior MRI-detected 
synovitis. For tenosynovitis, only the MCP and wrist joints 
were evaluated: 36% of joints (9 out of 25) had preceding 
tenosynovitis (online supplementary figure 1A-C).
Resolution of subclinical inflammation was observed despite 
progression to IA
Fourteen joints (in 11 different patients) had subclinical 
inflammation in the CSA phase which resolved over time, 
despite progression to IA at the patient level: an MRI 
example is provided in figure 2B.
However, the majority of joints assessed (N=227/350; 
65%) had no inflammation at either point in time 
(figure 1).
similar results observed for joints of ACPA-positive and 
ACPA-negative patients
As the pathogenesis of IA development presumably differs 
between ACPA-positive and ACPA-negative disease, anal-
yses were stratified for ACPA status. At the patient level, 
the interval between presentation with CSA and IA devel-
opment was shorter for ACPA-positive disease (median 
7 weeks, compared with 18 weeks in ACPA-negative 
disease). However, at the joint level the percentages of 
joints that progressed from subclinical inflammation 
to clinical synovitis were similar (online supplemen-
tary figure 2B). Likewise, analyses within ACPA-posi-
tive disease showed that 62% of joints with clinically 
apparent synovitis had no prior subclinical inflammation 
in the same joint, whereas in ACPA-negative disease this 
percentage was 72%.
Inflammation corrected for age-matched symptom-free 
persons yielded similar results (5% corrected definition)
Finally, a second definition of presence of MRI-de-
tected subclinical inflammation was used. The values of 
normality of MRI-detected joint inflammation depends 
on age and should take into account the occurrence of 
inflammation in symptom-free persons. Therefore, in 
this second definition (5% corrected definition), subclin-
ical inflammation was considered present after correc-
tion for the level of inflammation occurring in <5% of 
age-matched symptom-free persons at the same joint and 
for the same feature (a definition used previously1 11). 
With the 5% corrected definition, similar findings were 
obtained (online supplementary figure 3),3 with the 
majority of small joints (84%) that developed clinical 
synovitis having no preceding phase lasting for weeks 
with subclinical inflammation in the same joint.
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Figure 2 Examples of MRI at presentation with clinically suspect arthralgia (CSA) (top panel) and at IA development (bottom 
panel), showing joints (A) from no inflammation to clinical synovitis and (B) resolution of subclinical inflammation. Presented 
in (A) are: (top panel) left MCP joints with no subclinical inflammation as detected by MRI, and (bottom panel) left MCP joints 
of the same patient with synovitis in MCP5 and tenosynovitis in MCP2 and 5. According to clinical examination the patient 
developed clinical synovitis in the left MCP2 (depicted), left MCP5 (depicted), left proximal interphalangeal (PIP)2 and right PIP5 
joints (both not imaged). From a different patient (B) are presented: (top panel) right wrist joint with tenosynovitis in the extensor 
carpi ulnaris tendon, and (bottom panel) right wrist joint of the same patient without MRI-detected subclinical inflammation 
despite progression to inflammatory arthritis at the patient level. The patient developed clinically apparent synovitis in the 
left PIP3 joint (not imaged). All images were made in T1-weighted fast spin echo (FSE) sequence with frequency selective fat 
saturation in the axial plane after gadolinium contrast injection.
dIsCussIon
To our knowledge, this study was the first to perform 
longitudinal joint-level analyses in order to investigate 
progression of inflammation in patients converting from 
CSA to the earliest clinical phase of IA. At the joint level, 
only moderate correlations were observed between pres-
ence of subclinical inflammation and subsequent devel-
opment of clinical synovitis. The majority of joints with 
clinical synovitis had no subclinical inflammation in the 
same joint at the baseline observation.
The present joint-level observations on inflammatory 
progression fit best with the hypothesis of ‘global dereg-
ulation’, rather than that of a localised exacerbating 
process. Previous observations of increased markers of 
systemic inflammation in prearthritis phases may support 
this.12 Additionally, our study showed only moderate 
correlations between inflammation on MRI and progres-
sion of synovitis as assessed by physical examination, with 
BME showing the lowest proportion of prior subclin-
ical inflammation in the joints progressing to synovitis. 
Another study found that MRI-detected subclinical 
inflammation is present in clinically swollen joints and 
in non-swollen joints; in particular, BME frequently 
occurred in clinically non-inflamed joints.13
Our results should be interpreted within the context 
of some methodological limitations. Considering that 10 
joints (unilateral MCP, wrist and MTP joints) per patient 
were studied, many synovial joints were not assessed. 
Furthermore, the total sample size was limited despite 
large availability of data on joint level. However, this study 
offers the first and largest longitudinal scrutiny of data on 
joint inflammation in patients with arthralgia that prog-
ress to IA. Finally, the time interval between presentation 
with CSA and IA differed between individual patients, 
posing the possibility of dissimilarities in time intervals 
for joints with or without preceding subclinical inflam-
mation. Nonetheless, a GEE model incorporating each 
patient contributing 10 joints suggested no differences 
in time to arthritis for joints with or without preceding 
subclinical inflammation, indicating that results were not 
based on a few patients with longer time intervals.
An elementary, but sensitive, definition of subclinical 
inflammation (summed inflammation score ≥1 per joint) 
was used. Reference values of normality for MRI-detected 
joint inflammation depending on age, inflammatory 
feature and joint were not included in this definition. 
When subclinical inflammation was defined as inflam-
mation present in <5% of age-matched symptom-free 
persons at the same joint and for the same feature (5% 
corrected definition), similar findings were obtained.
ACPA-positive and ACPA-negative disease have different 
risk factors, presumed differences in pathogenesis and 
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known dissimilarities in speed in progressing from CSA 
to IA.14 However despite these differences, the observa-
tions on joint level on the relation between subclinical 
inflammation in the CSA phase and clinical synovitis in 
the IA phase were roughly similar in both groups. Larger 
studies validating these findings are required.
MRI depicts inflammation of different tissues around 
the joint. Stratified analyses showed that clinical synovitis 
was most often preceded by MRI-detected tenosynovitis. 
This fits previous observations that tenosynovitis had 
the highest predictive accuracy for RA development,1 
and that tenosynovitis was an initial preclinical change 
in mouse models of arthritis development.15 Although 
further studies are needed to explore this thoroughly, the 
combination of these findings suggests that tenosynovitis 
is a very early phenomenon.
The ability of a clinician to detect swollen joints may 
be dissimilar between different joint groups (MCP, wrist 
and MTP joints) analysed in this paper. Nevertheless, the 
number of swollen joints in the feet (MTP: 20 joints) was 
similar to the number of swollen joints in the hand (MCP 
and wrist: 25 joints). Future studies could investigate the 
correlation between MRI-detected subclinical inflamma-
tion in clinically swollen and non-swollen joints in the 
feet versus joints of the hand.
This study evaluated inflammation on MRI scans in 
individual joints over time. Future studies with serial MRI 
at more frequent time points (and thus shorter inter-
vals) in patients progressing from arthralgia to RA might 
further increase the understanding of inflammatory 
processes in small joints during IA development.
In conclusion, this first longitudinal MRI study on joint 
level during progression from CSA to IA indicates that 
the course of subclinical inflammation is variable and 
showed that the majority of small joints that developed 
clinical synovitis had no subclinical inflammation in the 
same joint at the baseline observation.
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